Loading
A phase 1/2 trial of CYNK-001 run by Celularity Incorporated, withdrawn before enrolling.
CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type is a phase 1/2 interventional study registered as NCT05218408 by Celularity Incorporated, started 2021-09. Conditions recorded: Astrocytoma, Grade IV, Glioblastoma, Giant Cell Glioblastoma and Glioblastoma Multiforme. Interventions recorded: CYNK-001 systemic and Intra cavity administration.
Shares CYNK-001, Celularity, Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares CYNK-001, Celularity and the tag pipeline.
Shares CYNK-001, Celularity and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/